OBJECTIVE: the objective of this study was to identify the risk factors for delays in chemotherapy after rectal cancer surgery and evaluate the effects of delayed therapy on long-term outcomes. We also sought to clarify what time frame should be used to define delayed adjuvant chemotherapy.
ranging from 18% to 38%. [2] [3] [4] [5] [6] hendren and colleagues 2 showed an association between postoperative complications and omission in chemotherapy in patients who have stage iii colon cancer from the surveillance epidemiology and end Results database. they also demonstrated that patients with complications were more likely to have a significant delay in chemotherapy >60 days. in addition to the association between complications and chemotherapy delays, multiple patient factors have been found to contribute to delays in patients with colorectal cancer, including older age, unmarried status, low socioeconomic status, and preoperative comborbidities. [7] [8] [9] [10] [11] [12] in the current literature, risk factors for delayed postoperative chemotherapy in patients with rectal cancer have not been well described.
although multiple studies have demonstrated that a delay in adjuvant chemotherapy is associated with worse outcomes, the definition of delay continues to be debated in the literature, and no standard timing has been established for patients who have rectal cancer. some studies have demonstrated improved overall survival in patients who receive adjuvant chemotherapy within 8 weeks of resection for colorectal cancer. [13] [14] [15] other studies have identified a decrease in overall survival when adjuvant therapy was delayed >12 weeks postoperatively. 11, 12 Clarification is needed to determine when patients who have rectal cancer should receive adjuvant chemotherapy for the best longterm outcomes.
the purpose of this study was to evaluate the effect of postoperative complications on survival in patients with rectal cancer. We also sought to clarify the time frame that constitutes a delay in adjuvant chemotherapy by evaluating long-term outcomes and to identify risk factors for delay in chemotherapy. finally, we evaluated the effects of delayed chemotherapy on disease-free and overall survival. We hypothesized that postoperative complications contribute to delays in chemotherapy and that receiving chemotherapy late is associated with worse overall and disease-free survival.
METHODS
Patients with rectal cancer who underwent proctectomy with total mesorectal excision between 1995 and 2012 at the university of Wisconsin were identified retrospectively from a prospectively maintained institutional review board-approved database. the human subjects committee at the university of Wisconsin has approved all investigations into this database. the database contained data on patients with primary rectal cancer including over 15 preoperative comorbidity categories, age, sex, race, admission, operative and discharge dates, preoperative staging, operative type, duration, blood loss, and histology. Recorded comorbid conditions included diabetes mellitus, smoking, dyspnea, preoperative functional status, ventilator dependence, chronic obstructive pulmonary disease, ascites within 30 days before surgery, congestive heart failure within 30 days before surgery, taking antihypertensive medications, acute renal failure, hemodialysis dependence, disseminated cancer, open wound, steroid/immunosuppressive medication use, body weight loss >10% in 6 months before surgery, bleeding disorder, transfusion of red blood cells within 72 hours before surgery, and sepsis within 48 hours before surgery. Patients were categorized according to the indication for chemotherapy based on clinical and pathologic staging in an effort to identify the group of patients in whom chemotherapy was omitted. indication for chemotherapy was defined as preoperative lymph node involvement on imaging, postoperative lymph node involvement on pathology, or the presence of metastatic disease. Given the time frame of our study and changing indications over this time, we did not include advanced t stage alone as an indication for chemotherapy. Patients with metastatic disease were included in the study population if they underwent resection with curative intent. the type and timing of chemotherapy was recorded, as was the timing of radiation if it was received. timing to postoperative chemotherapy was defined as the number of days between curative rectal cancer surgery and first chemotherapy administration. Preliminary analysis of chemotherapy timing revealed significant differences in patient outcomes with therapy delayed past 8 weeks; therefore, 8 weeks was used for the remainder of analyses as opposed to 12 weeks ( fig. 1 ). thirty-day postoperative complications including superficial, deep, and organ space surgical site infection, wound dehiscence, pneumonia, reintubation, pulmonary embolism, respiratory failure, acute renal failure, urinary tract infection, stroke, coma, neurologic deficit, cardiac arrest, myocardial infarction, postoperative bleeding requiring transfusion, deep vein thrombosis, and sepsis were recorded. Data for 30-day readmission to the hospital and reoperation within 30 days were also available. the database contained data on local and distant recurrence including site and timing of recurrence. mortality, as well as time of death, was recorded.
all statistical analyses were performed with the use of sPss statistics version 21. Descriptive statistics of patient characteristics, treatment, and outcomes were performed for the total patient population. univariate analysis using χ 2 testing was performed to evaluate for associations between explanatory variables and timing of chemotherapy. each of the comorbid conditions was evaluated separately, and, owing to comorbidity occurring rarely in this population, the presence of any comorbidity was also evaluated as an explanatory variable. the presence of serious comorbidity (congestive heart failure, ventilator dependence, preoperative ascites, and dialysis dependence) was extremely rare (5 of 355 patients), and, therefore, serious comorbidity was not evaluated separately. a multivariate analysis was not performed because significant colinearity was found between the only 2 explanatory variables with statistical significance in univariate analysis. Kaplan-meier curves were generated for the presence or absence of complications both in the total patient population and in the subset of patients who received chemotherapy. Kaplan-meier curves were created to evaluate the timing of chemotherapy in patients who had postoperative complications and in patients who did not develop postoperative complications. overall survival was also evaluated in the patients who received chemotherapy before 8 weeks with comparison of complications and no complications. a similar Kaplanmeier curve was generated in the patients who received chemotherapy after 8 weeks. Disease-free (local recurrence and distant recurrence) and overall survival were examined according to the timing of chemotherapy by using Kaplanmeier curves. Cox regression analysis was performed with the following possible confounders: postoperative complications, timing of chemotherapy, pathologic stage, margin status, neoadjuvant chemotherapy, and comorbidity. twosided p values of <0.05 were considered significant.
RESULTS

Patient Characteristics
We identified 355 patients who underwent proctectomy for rectal cancer at the university of Wisconsin hospitals and Clinics between 1995 and 2012. table 1 lists patient characteristics, treatment modalities, and outcomes for the total patient population. overall, 213 patients (60%) presented with locally advanced rectal cancer and were considered to have indications for chemotherapy. Chemotherapy was omitted in 73 patients (34%) who had indications for chemotherapy. one hundred eighty-three patients ultimately received postoperative chemotherapy, 136 of whom had indications for chemotherapy by the definition of this study.
Postoperative Complications and Survival
the overall complication rate in this patient population was 30% (107 of 355 patients). Patients with indications for chemotherapy had a similar complication rate of 30%, and those who received postoperative chemotherapy had a complication rate of 31%. surgical site infection was the most common complication in patients who received chemotherapy within 8 weeks (52% of complications) and patients who received chemotherapy after 8 weeks (54% of complications). Deep or organ space surgical site infection was more common in patients in the delayed chemotherapy group (6 patients) compared with those who received chemotherapy on time (2 patients). as demonstrated in figure 2 , postoperative complications were significantly associated with worse overall survival in both the total patient population (n = 355) and in patients who received postoperative chemotherapy (n = 165). in patients who received chemotherapy and had postoperative complications (Fig. 2B ), the median survival was 119.3 months (95% Ci, 47.1-191.5).
Risk Factors for Delay in Chemotherapy
of the 183 patients who received postoperative chemotherapy, the timing of treatment was known for 165 patients, who made up the chemotherapy study group. one hundred ten patients received chemotherapy within 8 weeks of surgery, and 55 patients received chemotherapy after 8 weeks. Patient characteristics, treatment modalities, and outcomes for patients who received chemotherapy at <8 weeks and ≥8 weeks following surgery are listed in table 2. these data suggest that postoperative complications and readmissions within 30 days of surgery are associated with delays in chemotherapy later than 8 weeks. in a separate univariate analysis, readmissions were found to be significantly associated with complications. a review of the data revealed that many of the same patients who had postoperative complications were also readmitted. Because of the colinearity between these factors and the lack of other statistically significant explanatory variables, further multivariate analysis was not performed. figure 3a provides the Kaplan-meier curve for overall survival in patients who experienced postoperative complications and received chemotherapy at <8 weeks and ≥8 weeks. the median survival for patients with com- (unable to calculate 95% Ci). figures 3C and 3D show overall survival in patients with and without complications in the subset of patients who received chemotherapy on time (n = 109) and those whose chemotherapy was delayed (n = 55). in the delayed group, the median survival for patients without complications was 78.7 months in comparison with 59.1 months in patients with complications (95% Ci, 13.1-105.1). these data show that the risk of death was significantly greater for patients with complications who received adjuvant chemotherapy at ≥8 weeks compared with <8 weeks. in patients without complications, a similar trend in worse overall survival at ≥8 weeks was observed, but it lacked statistical significance. Complications did not have an effect on overall survival when comparing patients who received chemotherapy in a similar time frame whether it was received on time or delayed. figure 4 demonstrates local and distant recurrence-free survival in patients who received adjuvant chemotherapy at <8 weeks and later than 8 weeks following surgery (n = 165). the median time to local recurrence in the patients who received chemotherapy on time was 195.8 months, and in patients who received delayed therapy the median time to recurrence was 142.1 months (95% Ci, 107.6-176.6). figure 5 shows overall survival in patients who received chemotherapy before and after 8 weeks (n = 165). the median survival in patients who received delayed chemotherapy was 77.5 months (95% Ci, 53.1-101.9). a Cox regression analysis was performed with the following potential cofounders: timing of chemotherapy, pathologic stage, margin status, neoadjuvant chemotherapy, comorbidity and postoperative complications; delays in chemotherapy remained a significant predictor of survival, local recurrence ,and distant recurrence (table 3) . these data suggest that delays in chemotherapy ≥8 weeks are associated with worse disease-free and overall survival.
Complications and Chemotherapy Timing
Long-term Outcomes With Delayed Chemotherapy
DISCUSSION
the aim of this study was to describe the timing of chemotherapy in patients who have rectal cancer, risk factors for delayed therapy, and the differences in outcomes in patients who received adjuvant chemotherapy on time compared with delayed. We found that postoperative complications are associated with delays in chemotherapy and worse overall survival in patients with rectal cancer. We also identified the differences in recurrence-free survival and overall survival in patients who received chemotherapy ≥8 weeks after surgery for rectal cancer. We found a significant association between postoperative complications and delays in postoperative chemotherapy. a similar relationship has been previously described in patients with colon cancer, 2 but to our knowledge this association has never been established in patients with rectal cancer. other authors have identified patient characteristics as risk factors for delays in chemotherapy such as older age, low socioeconomic status, medical comorbidities, and single status. [7] [8] [9] [10] [11] [12] We did not uncover an association between age or medical comorbidities and delayed chemotherapy in our study. other studies that identified patient age and comorbidities as risk factors for delayed therapy 12, 14 were performed in older patients (>65 years of age), which may explain this discrepancy. the patient population in our study was relatively young, average age 60, and had very little comorbidity.
it has been well established in the literature that delaying chemotherapy more than 8 to 12 weeks has resulted in worse overall survival in patients who have colorectal cancer. [11] [12] [13] [14] [15] We not only identified an association between the administration of chemotherapy ≥8 weeks after surgery and overall survival, but also a significant association between delayed therapy and disease-free survival. Cheung et al 12 and hershman et al, 14 both using the surveillance epidemiology and end Results database, also found worse overall and disease-free survival in patients with rectal cancer who received delayed adjuvant chemotherapy >12 weeks. other authors who have found differences in overall survival have not found differences in disease-free survival.
11,15 these differences in outcomes may reflect different patient populations, different disease stages, and the fact that previous studies have not been performed exclusively in patients with rectal cancer.
interestingly, patients in this study who received delayed chemotherapy had significantly higher incidences of local recurrence in comparison with patients who received chemotherapy on time. historically, radiation therapy and total mesorectal excision have been credited with decreasing local recurrence in patients with rectal cancer, not chemotherapy. [17] [18] [19] if this finding could be replicated in a larger multicenter patient population, it may provide evidence for narrowing adjuvant therapy to chemotherapy alone with an emphasis on administering therapy within 8 weeks of surgery.
although our findings that postoperative complications are associated with worse patient outcomes were not unexpected, we were interested in trying to elucidate the mechanism in which complications correlate with worse disease-free and overall survival. We hypothesized that postoperative complications would lead to delays in chemotherapy resulting in worse disease-free and overall survival. Postoperative complications were found to significantly correlate with delays in chemotherapy in univariate analysis in this study. of patients with complications, those who had delays in chemotherapy had worse overall survival, suggesting that delay in chemotherapy is what ultimately affects longer-term outcomes. Patients without complications were also found to have worse overall survival with delayed chemotherapy, which did not reach statistical significance. Complications did not significantly affect overall survival in patients who received chemotherapy during similar time periods following surgery. this leads us to believe that postoperative complications indirectly influence outcomes by leading to delays in chemotherapy administration. We acknowledge that there are many possible confounding factors associated with mortality and recurrence rates in this patient population. although we took into consideration some potential confounding factors using Cox regression analysis, there are likely many more patient and tumor factors that influence long-term outcomes in patients with rectal cancer. We were also unable to ascertain the duration of chemotherapy in these patients, because many patients received treatment at other facilities. it would be interesting to know if patients who undergo delayed chemotherapy are also less likely to complete a full course of therapy. We hypothesize that shortened courses of chemotherapy would be associated with worse outcomes in these patients. future studies in a larger patient population would be useful to further assess the impact of surgeon and patient factors, as well as the duration and completion of chemotherapy on outcomes in patients with rectal cancer.
this study has limitations inherent to a retrospective database review and may not account for patient variables that were not recorded in our institutional rectal cancer database. for example, this database did not capture explanations for why chemotherapy was delayed, and only 18 different categories of postoperative complications were recorded. We were also not able to capture complete data on all patients during the study period, although the timing of chemotherapy was known for 90% of our study patients. the study was performed at a single institution in a small number of patients which may limit the generalizability of the results. a potential source of bias stems from the lack of protocols to determine which patients received chemotherapy with 26% of patients who received chemotherapy lacking indications as defined by this study. the inclusion of these patients may therefore overestimate the impact of delays. on the other hand, we have not included patients for whom chemotherapy was omitted, which may underestimate the effects of delays. finally, the study population was not large enough to further classify complications in an effort to identify which specific complications lead to delays.
CONCLUSION
We have demonstrated an association between postoperative complications and delays in chemotherapy ≥8 weeks in patients with rectal cancer. We have also shown that delaying therapy influences long-term outcomes in these patients. further studies are needed to identify which postoperative complications are most likely to lead to delays in therapy and to further analyze why patients receive chemotherapy late in an effort to improve long-term outcomes in patients with rectal cancer.
